GENPF.US Genix Pharmaceuticals Corporation
- Market cap
- USD 637K
- P/E
- -
- P/B
- 1.57x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Apr 2026.
Is GENPF.US undervalued?
Graham numberThe Graham number of Genix Pharmaceuticals Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genix Pharmaceuticals Corporation fundamental analysis
No fundamental analysis for Genix Pharmaceuticals Corporation yet.
Genix Pharmaceuticals Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, …
Full company profileGenix Pharmaceuticals Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Apr 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genix Pharmaceuticals Corporation annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 925K | 1.01M | 420K | 137K | 0.00 | 0.00 | 0.00 | 12.3K | 4.05K | 0.00 | 0.00 |
| Gross Profit | 411K | 499K | 92.7K | -45.7K | -362K | -537K | -564K | 3.26K | 1.30K | -1.13K | - |
| Operating Income | -140K | -282K | -26.1K | -143K | -716K | -1.65M | -1.03M | -881K | -241K | -153K | -101K |
| EBITDA | -83.2K | -29.1K | -23.9K | -163K | -318K | -1.12M | -434K | -3.80M | 49.1K | -152K | -100K |
| Net Income | -129K | -243K | 134K | -165K | -719K | -1.65M | -1.07M | -4.40M | -73.2K | -335K | -260K |
| EPS | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | -0.03 | -0.02 | -0.07 | 0.00 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 452K | 394K | 232K | 40.3K | 5.35M | 4.77M | 4.25M | 223K | 45.6K | 51.0K | 33.3K |
| Total Liabilities | 68.0K | 273K | 109K | 82.4K | 490K | 755K | 1.05M | 1.36M | 1.23M | 1.47M | 1.58M |
| Shareholders' Equity | 384K | 121K | 123K | -42.1K | 4.86M | 4.01M | 3.20M | -1.14M | -1.18M | -1.42M | -1.55M |
| Cash & Short-term Investments | 112K | 101K | 69.9K | 31.3K | 697K | 139K | 9.27K | 11.6K | 11.5K | 43.6K | 11.3K |
| Total Debt | - | - | - | 20.6K | 15.2K | 48.9K | 183K | 512K | 816K | 699K | 770K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -165K | -9.35K | 34.2K | -58.6K | -195K | -428K | -220K | -221K | -187K | -124K | -93.1K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 3.34K | 0.00 | 0.00 | 0.00 | 8.16 |
| Free Cash Flow | -165K | -9.35K | 34.2K | -58.6K | -203K | -428K | -223K | -221K | -187K | -124K | -93.1K |
| Ratios | |||||||||||
| ROE | -33.6% | -201.0% | 109.4% | - | -14.8% | -41.2% | -33.6% | - | - | - | - |
| ROA | -28.5% | -61.8% | 57.9% | -408.9% | -13.4% | -34.6% | -25.3% | -1,967.0% | -160.7% | -657.2% | -780.3% |
| Net Profit Margin | -14.0% | -24.1% | 31.9% | -119.9% | - | - | - | -35,600.3% | -1,806.9% | - | - |
| Debt to Equity | - | - | - | - | 0.00x | 0.01x | 0.06x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genix Pharmaceuticals Corporation dividends
Genix Pharmaceuticals Corporation has not paid dividends in the last 9 fiscal years.
Who owns Genix Pharmaceuticals Corporation
- Insiders 46.92%
- Institutions 0.00%
- Public & others 53.08%
- Shares outstanding 61.2M
- Free float 33.4M
Genix Pharmaceuticals Corporation company profile
- Company name
- Genix Pharmaceuticals Corporation
- Ticker
- GENPF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- October
- Address
- 1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9
- Phone
- 604-609-6198
- Website
- genixpharm.com
About Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, a dietary supplement to support kidney health; Sucanon, an herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults; and Synthroid, a levothyroxine sodium drug for the treatment of hypothyroidism. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.
Genix Pharmaceuticals Corporation management
4- Mr. Mahmoud S. AzizChairman of the Board & President · born 1958
- Mr. Sina Salehi PiroozCEO & Director
- Mr. Kevin James BottomleyDirector of Corporate Development & Independent Director · born 1978
- Ms. Raylen TamayoChief Financial Officer